Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Shi, Jimin  [Clear All Filters]
Journal Article
Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, Huang H, Zhao Y. TP53 in MDS and AML: Biological and clinical advances. Cancer Lett. 2024:216767.
Wu L, Wu Y, Shi J, Lai X, Zhao Y, Liu L, Yu J, Yang L, Zhu P, Zheng W, et al. Survival and late mortality among patients who survived disease-free for 2 years after stem cell transplantation. Br J Haematol. 2023.
Chen W, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Huang H, Zhao Y. Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma. Bone Marrow Transplant. 2024.
Pan M, Wu Y, Yang L, Zhu P, Shi J, Lai X, Liu L, Zhao Y, Yu J, Huang H, et al. Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients. Ann Hematol. 2024.
Gao Y, Wu H, Shi Z, Gao F, Shi J, Luo Y, Yu J, Lai X, Fu H, Liu L, et al. Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
Yang L, Zhang Z, Jiang P, Kong D, Yu Z, Shi D, Han Y, Chen E, Zheng W, Sun J, et al. Phase separation-competent FBL promotes early pre-rRNA processing and translation in acute myeloid leukaemia. Nat Cell Biol. 2024.
Shi Z, Gao F, Ding D, Wu H, Shi J, Luo Y, Yu J, Tan Y, Lai X, Liu L, et al. Outcomes of haploidentical peripheral blood stem cell transplantation following myeloablative conditioning using two types of rabbit ATG: a propensity score-matched analysis. Ann Hematol. 2024.
Jiang B, Zhao Y, Luo Y, Yu J, Chen Y, Ye B, Fu H, Lai X, Liu L, Ye Y, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring Rearrangement and Its Prognostic Factors. Cell Transplant. 2024;33:9636897231225821.
Wu Y, Shi J, Tan Y, Zhao Y, Yu J, Lai X, Yang L, Huang H, Luo Y. A novel strategy for the prevention of HBV-related hepatitis following allogeneic hematopoietic stem cell transplantation from HBsAg-positive donors lantation from HBsAg-positive donors. Biol Blood Marrow Transplant. 2020.
Chen W, Huang J, Zhao Y, Huang L, Yuan Z, Gu M, Xu X, Shi J, Luo Y, Yu J, et al. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study. J Transl Med. 2024;22(1):410.
Ye Y, Labopin M, Chen J, Wu D, Gedde-Dahl T, Blaise D, Socié G, Forcade E, Salmenniemi U, Maury S, et al. Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT. Blood Cancer J. 2024;14(1):85.
Gao F, Shi J, Luo Y, Tan Y, Lai X, Yu J, Huang H, Zhao Y. The incidence, Risk factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Xu X, Zu C, Zhang M, Xiao P, Hong R, Feng J, Xu H, Cui J, Yu J, Shi J, et al. HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma. Cell Transplant. 2023;32:9636897231194265.
Wu H, Zhao Y, Gao F, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Qian P, et al. Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis. J Transl Med. 2023;21(1):329.
Cao L, Shi J. [Graft failure in allogeneic hematopoietic stem cell trans-plantation]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018;47(6):651-658.
Zeng X, Li X, Li X, Wei C, Shi C, Hu K, Kong D, Luo Q, Xu Y, Shan W, et al. Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation. Blood. 2023.
Liu L, Ji X, Zhu P, Yang L, Shi J, Zhao Y, Lai X, Yu J, Fu H, Ye Y, et al. Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2023.
Gao F, Shi Z, Shi J, Luo Y, Yu J, Fu H, Lai X, Liu L, Yuan Z, Zheng Z, et al. Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation. HLA. 2023.
Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, et al. Determining whether prophylactic antiviral treatment is necessary in HBsAg-negative/HBcAb-positive patients receiving allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Yang T, Jiang B, Luo Y, Zhao Y, Ouyang G, Yu J, Lan J, Lu Y, Lai X, Ye B, et al. Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. Am J Hematol. 2023.
Guan F, Yang L, Chen Y, Shi J, Song X, Lai X, Lu Y, Liu L, Ouyang G, Zhao Y, et al. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer. 2024.
Yan M, Su F, Cheng F, Shi J, Zheng W, Luo Y, Wang J, Lu H, Zhou H, Huang H, et al. Chronic graft-versus-host disease-related polymyositis and myocarditis: A case report and review of the literature. Transpl Immunol. 2022:101598.
Zhao Y, Shi J, Luo Y, Gao F, Tan Y, Lai X, Yu J, Wei G, Huang H. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Liu W, Ji J, Zou D, Cao Y, Xu Y, Zhou J, Gao S, Wang F, Chen W, Du J, et al. Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China. Bone Marrow Transplant. 2022.